Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMDNASDAQ:LYRANASDAQ:NDRANASDAQ:TNON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$0.38-4.6%$0.38$0.24▼$1.06$6.10M1.932.34 million shs367,144 shsLYRALyra Therapeutics$0.09-4.4%$0.11$4.10▼$17.20$5.82M0.0437,650 shs1.85 million shsNDRAENDRA Life Sciences$3.17+1.9%$4.12$2.90▼$577.50$2.30M0.19140,740 shs89,934 shsTNONTenon Medical$1.11$1.31$0.91▼$15.79$8.43M1.232.48 million shs103,219 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-4.62%-7.44%-0.47%-34.66%-9.64%LYRALyra Therapeutics-4.36%-8.92%-16.38%-57.21%-73.03%NDRAENDRA Life Sciences+1.93%+2.26%-20.35%-32.35%-99.99%TNONTenon Medical0.00%-5.13%-5.13%-21.83%+49.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical2.3828 of 5 stars3.53.00.00.02.70.01.3LYRALyra Therapeutics2.9899 of 5 stars3.23.00.00.04.11.71.3NDRAENDRA Life Sciences1.9234 of 5 stars3.52.00.00.02.00.01.3TNONTenon Medical2.1722 of 5 stars3.53.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 3.00Buy$7.001,744.53% UpsideLYRALyra Therapeutics 2.33Hold$2.002,177.90% UpsideNDRAENDRA Life Sciences 3.00Buy$50.001,477.29% UpsideTNONTenon Medical 3.00Buy$4.67320.42% UpsideCurrent Analyst Ratings BreakdownLatest NDRA, LYRA, TNON, and AEMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025TNONTenon MedicalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.004/9/2025TNONTenon MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.003/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/10/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K10.69N/AN/A$2.19 per share0.17LYRALyra Therapeutics$1.19M4.91N/AN/A$1.56 per share0.06NDRAENDRA Life SciencesN/AN/AN/AN/A$1,170.18 per shareN/ATNONTenon Medical$3.28M2.57N/AN/A$2.39 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.21M-$1.58N/AN/AN/AN/A-153.96%-109.13%6/26/2025 (Estimated)LYRALyra Therapeutics-$62.68M-$1.21N/AN/AN/A-6,635.76%-125.07%-59.74%8/12/2025 (Estimated)NDRAENDRA Life Sciences-$10.06M-$172.04N/AN/AN/AN/A-127.39%-103.77%8/13/2025 (Estimated)TNONTenon Medical-$15.58M-$27.23N/A∞N/A-413.88%-1,785.88%-164.26%8/11/2025 (Estimated)Latest NDRA, LYRA, TNON, and AEMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TNONTenon Medical-$1.06-$1.01+$0.05-$1.01$0.76 million$0.73 million5/6/2025Q1 2025LYRALyra Therapeutics-$0.15-$0.12+$0.03-$0.13$0.16 million$0.18 million3/31/2025Q4 2024NDRAENDRA Life Sciences-$4.10-$9.40-$5.30-$20.78N/AN/A3/13/2025Q4 2024LYRALyra Therapeutics-$0.12-$0.16-$0.04-$0.16$0.21 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ATNONTenon MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A2.802.80LYRALyra TherapeuticsN/A3.643.64NDRAENDRA Life SciencesN/A6.106.10TNONTenon MedicalN/A3.523.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%LYRALyra Therapeutics95.62%NDRAENDRA Life Sciences1.19%TNONTenon Medical22.74%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.10%LYRALyra Therapeutics3.25%NDRAENDRA Life Sciences0.04%TNONTenon Medical4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical1016.06 million14.30 millionNo DataLYRALyra Therapeutics5066.27 million62.39 millionOptionableNDRAENDRA Life Sciences20738,000537,000Not OptionableTNONTenon Medical87.59 million2.99 millionNot OptionableNDRA, LYRA, TNON, and AEMD HeadlinesRecent News About These CompaniesTenon Medical, Inc.: Tenon Medical Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deTenon Medical, Inc.: Tenon Medical Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deTenon Medical, Inc. (TNON) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comTenon Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | accessnewswire.comTenon Medical, Inc. Announces Timing of First Quarter 2025 Financial ResultsApril 29, 2025 | accessnewswire.comAlliance Global Partners Initiates Coverage of Tenon Medical (TNON) with Buy RecommendationApril 10, 2025 | msn.comTenon Medical initiated with a Buy at Alliance Global PartnersApril 9, 2025 | markets.businessinsider.comTenon Medical files to sell 5.67M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comTenon gets FDA clearance for Catamaran SI Joint Fusion System indicationMarch 26, 2025 | markets.businessinsider.comTenon Medical prices $2.5M registered direct offering at $2.00March 26, 2025 | markets.businessinsider.comFDA clears Tenon Medical’s Catamaran system expansionMarch 26, 2025 | investing.comTenon Medical dips 6%, prices $2.5M direct offeringMarch 26, 2025 | msn.comTenon Medical earns expanded indication for SI joint fusion systemMarch 25, 2025 | beckersspine.comTenon Medical Shares Jump After FDA Clears Joint Drug for Broader UseMarch 25, 2025 | marketwatch.comTenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesMarch 25, 2025 | accessnewswire.comTenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesMarch 25, 2025 | accessnewswire.comTenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal FusionMarch 24, 2025 | accessnewswire.comTenon Medical, Inc. (NASDAQ:TNON) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comEarnings call transcript: Tenon Medical’s Q4 2024 results show revenue growthMarch 22, 2025 | uk.investing.comTenon Medical, Inc.: Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNDRA, LYRA, TNON, and AEMD Company DescriptionsAethlon Medical NASDAQ:AEMD$0.38 -0.02 (-4.62%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.38 0.00 (-0.13%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Lyra Therapeutics NASDAQ:LYRA$0.09 0.00 (-4.36%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.09 0.00 (-0.80%) As of 05/27/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.ENDRA Life Sciences NASDAQ:NDRA$3.17 +0.06 (+1.93%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$3.15 -0.02 (-0.63%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Tenon Medical NASDAQ:TNON$1.11 0.00 (0.00%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.45%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Advance Auto Parts: Did Earnings Defuse Tariff Concerns? Apple Sinks After New 25% Tariff Announcement—What's The Bottom? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
